Navigation Links
CryoLife Announces First Clinical Use of BioFoam(R)
Date:9/10/2009

ding statements regarding hopes that BioFoam will reduce the time required to achieve hemostasis during liver resection surgery and reduce the number of complications following surgery, potential distribution timing and uses and applications for BioFoam and timing of enrollment in the feasibility phase of the Company's BioFoam IDE submission. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that BioFoam may not prove safe or effective for its intended uses, that BioFoam may not achieve hemostasis in liver resections or reduce complications following surgery due to any number of factors that we will not be able to identify until further procedures are performed, that BioFoam may not be useful in other future surgical applications, that the Company may not start feasibility phase enrollment in quarter 4 of 2009 due to any number of factors, including unanticipated delays in obtaining FDA and U.S. Department of Defense approval, and that BioFoam development may not result in a commercial product on the time table anticipated, or at all, due to factors beyond our control, including potential lack of acceptance by the medical community. For additional risks impacting the Company's business, see the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's subsequent Form 10-Q filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

    Media Contacts:

    D. Ashley Lee
    Executive Vice President, Chief Financial
    Officer and Chief Operating Officer
    Phone:  770-419-3355

    Dana H
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
2. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
4. CryoLife Reports Record First Quarter Revenues of $26.7 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
6. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
7. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
8. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
9. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
10. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
11. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... synthetic biology covers the designing and engineering of completely ... the redesigning of natural biological systems that provide improved ... form of extreme genetic engineering because it not only ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Immunomic Therapeutics, ... researchers to further develop potential treatments for glioblastoma multiforme ... in combination with their patented vaccine platform, LAMP-vax. ... University, are based on the work of John H. ... at The Preston Robert Tisch Brain Tumor Center at ...
(Date:7/28/2014)... Appistry, Inc. , a leading provider ... of genomics to next-generation medicine, announced today its judging ... , Two Appistry staff will be joined by ... Genome Resources, and Mr. Neil Miller, director of informatics ... Rounding out the panel are Appistry’s Dr. Richard Mazzarella, ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... SOUTH SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, ... advances in cardiovascular disease, inflammatory disease,and cancer, today ... of novel,compounds that inhibit spleen tyrosine kinase (Syk) ... be presented at the annual meeting of the,American ...
... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... 3:30 p.m. Eastern Time on Wednesday,December 10, 2008. The event will ... of the Medarex website at www.medarex.com . An,archived edition of ... About Medarex , ...
... markets, the trend in health care employment could be counted on ... bringing yearly growth up over 345,000.The MedZilla.com Employment Report analyzes the ... ... Seattle, WA (Vocus) December 3, 2008 -- The U.S. economy ...
Cached Biology Technology:Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 3
(Date:7/28/2014)... RENO Norwegian explorer Roald Amundsen became the first ... 1911. More than 100 years later, an international team ... Research Institute (DRI) have proven that air pollution from ... 16 ice cores collected from widely spaced locations around ... created the most accurate and precise reconstruction to date ...
(Date:7/27/2014)... survived the asteroid strike that wiped them out if ... history, scientists say. , A fresh study using up-to-date ... to build a new narrative of the prehistoric creatures, ... that in the few million years before a 10km-wide ... environmental upheaval. This included extensive volcanic activity, changing sea ...
(Date:7/27/2014)... a new species of mayfly in the southern Western Ghats, ... fact, this is the first time that any mayfly belonging ... peninsular India. , The new species, called Labiobaetis soldani ... his substantial contribution to the understanding of the Ephemeroptera of ... study that describes the new mayfly in the Journal ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... 23andMe, the leading personal genetics company, announces the ... Neil Rothstein as Vice President Marketing, and Jonathan ... company,s executive leadership team. As ... the company,s corporate communications, media relations and investor ...
... Oct. 17, 2012 Rising crime rates and ... increase monitoring and introduce reliable border control systems. ... criminal identification and automated immigration at all entry ... adoption in the government vertical across Asia-Pacific. ...
... 24, 2012  Aware, Inc. (NASDAQ: AWRE ), ... assurance products, today reported financial results for its third ... our DSL service assurance hardware business have been reported ... the shutdown of that business during the third quarter. ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... standard for whole-blood clinical diagnostic work in ... less, this analyzer makes precise glucose measurements ... precise lactate measurements of whole blood, plasma, ... option allows you to have glucose results ...
... The first high-density serum biomarker chip to ... proteins. An antibody chip containing 120 human ... that enables biomarker discovery scientists to study ... benefits of therapy and the likelihood of ...
... description: The Costar strip ejector is a ... of Costar strips from their holder. Linkage: ... number, created to easily match Cornings product ... order under the old Sigma-Aldrich number (Z71,314-7) ...
Biology Products: